Response Genetics Inc (RGDXQ) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Exhibit 99.1

FOR IMMEDIATE RELEASE

Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results

Response DX Revenue increased 16% and 22% over Fourth Quarter and Full Year 2013 Respectively

LOS ANGELES, March 31, 2015

Total revenue for the fourth quarter ended December 31, 2014 was $4.1 million compared to $4.8 million for the quarter ended December 31, 2013. The Company’s ResponseDX^® revenue was $3.7 million compared to $3.2 million for the quarter ended December 31, 2013, an increase of 15.6%. The Company’s pharmaceutical client revenue, which varies significantly on a quarterly basis by its nature and concentration, was $0.4 million for the quarter ended December 31, 2014 versus $1.6 million for the fourth quarter of 2013.

The Company believes its ResponseDX^® revenues are increasing as a result of the Company’s planned and implemented service offerings and accelerated focus and sales emphasis on larger accounts. To this end, the Company began seeing results in 2014 of what it believes is the best-in-class TC/PC testing service. With this service, the Company provides the technical component (TC), or the processing of patient samples, for interpretation by the sending pathologists, the professional component (PC). In addition to its TC/PC testing service, the expansion of the Company’s testing menu and the introduction of the ResponseDX: Tissue of Origin^® test, as well as other initiatives in process, the Company expects to add further volume to its sales base. The decrease in pharmaceutical client revenue relative to the quarter ended December 31, 2013 primarily relates to the timing of services performed for the Company’s largest pharmaceutical client.

As a result of the decreased pharmaceutical revenues in the fourth quarter of 2014, the Company’s gross margin decreased to 40% for the quarter ending December 31, 2014 compared to 48% for the fourth quarter of 2013.

Excluding cost of revenue, total operating expenses for the fourth quarter 2014 were $4.7 million, compared to $5.4 million, for the same period last year, a decrease of 13%, primarily as a result of cost containment policies implemented by the Company throughout the organization.

The Company’s net loss for the quarter ended December 31, 2014 was $3.4 million, or $(0.09) per share, compared to a net loss of $3.2 million, or $(0.09) per share, for the quarter ended December 31, 2013.

Total revenue for the year ended December 31, 2014 was $16.7 million compared to $19.8 million for the year ended December 31, 2013. 2014 ResponseDX^® revenues increased $2.6 million or 22% over 2013, offset by a $5.7 million decrease in pharmaceutical client revenue.